|
2010-12-27 |
188Re-marked Ior C5 MAb in persistent or relapsing ovary epithelial cancer, phase I. |
CIM |
Registered |
|
2010-12-27 |
Clinical trial, phase II: Evaluation of TheraCIM hR3 MaB combined with chemo- and radio-therapy to treat patients with epithelial tumors in neck of the uterus, stage III. |
CIM |
Registered |
|
2010-12-17 |
Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide, phase I. |
CIM |
Registered |
|
2010-12-17 |
NGcGM3/VSSP/Montanide ISA 51 vaccine in metastatic breast cancer. Phase II |
CIM |
Registered |
|
2010-12-17 |
99mtc-marked 14f7 MAb in colon/rectum tumor, Phase II |
CIM |
Registered |
|
2010-12-17 |
NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III. |
CIM |
Registered |
|
2010-12-17 |
Use of h-R3 monoclonal antibody and radiotherapy to treat patients with advanced epithelial head and neck tumors. |
CIM |
Registered |
|
2013-06-19 |
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors |
CIM |
Registered |
|
2013-06-20 |
EGF vaccine- Advanced Lung tumors |
CIM |
Registered |
|
14/12/2015 |
CIMAvax-EGF vaccine Predictor Phase IV |
CIM |
Registered outdated |
|
03/03/2023 |
Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS) |
CIM |
Registered |
|
03/11/2017 |
Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I |
CIM |
Registered |
|
17/02/2017 |
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors |
CIM |
Registered |
|
07/03/2018 |
14F7 in chronic B-cell lymphoproliferative syndrome |
CIM |
Registered |
|
12/05/2020 |
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab |
CIM |
Registered outdated |
|
07/12/2016 |
NGcGM3/VSSP in small cell lung cancer |
CIM |
Registered outdated |
|
15/11/2016 |
EC122 HER-1 Prostate Phase I |
CIM |
Registered |
|
07/12/2016 |
NGcGM3/VSSP in Metastatic melanoma |
CIM |
Registered |
|
05/11/2013 |
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma |
CIM |
Registered outdated |
|
23/05/2014 |
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. |
CIM |
Registered |
